Analyst Viewpoint
Increase in incidence of sinusitis is a prominent factor driving the global sinusitis treatment market growth. Sinusitis treatment narrows blood vessels, thereby helping reduce swelling that is responsible for sinus congestion.
Speedy approval of medications related to sinus infection treatment by regulatory bodies such as the U.S. FDA is also augmenting the sinusitis treatment industry size.
Leading players operating in the global sinusitis treatment market are entering into collaborations with various hospitals and research centers to devise new technologies such as 3D navigation technology to reduce errors and complications during functional endoscopic sinus surgery (FESS).
They are also observing the latest sinusitis treatment industry trends and introducing new drugs that help improve patient outcomes through differentiated dosage forms.
Sinusitis can be chronic, sub-acute, or acute, with various germs such as viruses and bacteria blocking the nasal cavities or filling them with fluid if left untreated. Furthermore, sinusitis can progress to complications such as meningitis or brain abscess if left untreated.
Diagnostics available include sinus MRIs, sinus CT scans, nasal cytology testing, ciliary function tests, and blood tests. Sinusitis treatment market share by treatment type is divided among decongestants, antibiotics, and surgery.
Various medications are available for the three types of treatments mentioned above. These include nasal corticosteroids and nasal sprays. As per the article titled ‘Chronic Sinusitis’ published in June 2021, those suffering from chronic sinusitis are administered corticosteroids after sinus surgery.
Besides, a new line of nasal sprays has been introduced, which help deliver drugs to cavities of sinuses that are difficult to reach. Optinose XHANCE has developed one such nasal spray that patients can use comfortably at home. Introduction of such innovations is fueling sinusitis treatment market dynamics.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Sinusitis is usually caused by common cold. A stuffy and blocked nose may block the sinuses and avert drainage of the mucus.
Air pollution is also a major cause of sinusitis. Inhalation of pollutants causes them to accumulate on mucus and get absorbed in nasal mucosa, thereby resulting in various detrimental effects such as sinusitis.
T suppressor cell is one of the most sensitive cells of the immune system and the first one to be adversely affected by exposure to chemical pollutants. As per the BMJ, 90% of the global population inhales air exceeding WHO targets regarding particulate matter.
Research states that the incidence of sinusitis stands at 15 episodes to 40 episodes/1,000 patients every year, and contributes to 0.5% of upper respiratory tract infections.
As per the CDC, 28.9 million adults in the U.S. are suffering from sinusitis. The CDC further states that the number of visits to physician by those contracting chronic sinusitis stands at 2.7 million.
According to the World Allergy Organization, acute sinusitis has an annual frequency of 6% to 15% worldwide. Thus, significant rise in incidence of sinusitis in the wake of a noticeable increase in air pollution is driving the sinus pain relief market.
Companies operating in the global sinusitis treatment market are raising their innovation quotient (IQ) by launching new sinus treatment products. Many of these drugs are being promptly approved by regulatory bodies.
In August 2020, Novartis’ Xolair (omalizumab) was approved by the EC as an add-on therapy with corticosteroids to treat chronic rhinosinusitis with nasal polyps. This is one of the primary drugs in the rhinosinusitis treatment market.
In August 2020, Satsuma Pharmaceuticals, Inc. announced that it had initiated patient enrolment in ASCEND trial, a 12-month, multi-center, open-label study to evaluate tolerance and safety of STS101 (dihydroergotamine [DHE] nasal powder) as an acute treatment for migraine.
In May 2020, the U.S. FDA approved Valtoco (diazepam nasal spray) to treat cluster seizures. In January 2020, Lyra Therapeutics, Inc. announced that the U.S. FDA had approved its investigational new drug (IND) application regarding LYR-210 to treat chronic rhinosinusitis (CRS).
In January 2020, Lannett Company, Inc. declared that it had obtained approval from the U.S. FDA for marketing Numbrino, a topical solution for mucus membranes in nasal activities.
Thus, quick approval process is a prominent factor that is bolstering the sinusitis treatment market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest sinusitis treatment market analysis, North America accounted for significant share of the global landscape in 2022. The region is likely to maintain its leading position during the forecast period.
Large sinusitis treatment market share of North America can be ascribed to the increase in number of individuals in the U.S. suffering from acute sinusitis. People in the U.S. prefer OTC drugs such as nasal corticosteroids, nasal sprays, and decongestants to treat sinusitis.
Europe also recorded substantial market progress in 2022, led by the rise in incidence of chronic sinusitis, availability of cutting-edge technologies related to the treatment of sinusitis, and increase in adoption of minimally invasive surgeries in the region.
The sinusitis treatment market forecast appears promising in Asia Pacific. Surge in chronic respiratory disorders in countries such as China and India is augmenting market statistics of the region.
Companies operating in the global sinusitis treatment industry are engaged in new drug developments to cater to the increase in demand for sinusitis treatment medications across the globe.
They are introducing a combination of therapies such as medical and surgical treatments, including sinus irrigation, antibiotics, steroid nasal sprays, short-term oral corticosteroids, and endoscopic sinus surgery, that target symptoms.
Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy’s Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Abbott Laboratories, Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co., Inc., AstraZeneca plc, Amneal Pharmaceuticals LLC, GlaxoSmithKline plc, Apotex, Inc., Hikma Pharmaceuticals plc, Wockhardt, and Mylan N.V. are prominent players functioning in the global landscape.
These firms have been profiled in the market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 2.1 Bn |
| Market Forecast (Value) in 2031 | US$ 3.5 Bn |
| Growth Rate (CAGR) | 5.8% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Reque |
It was valued at US$ 2.1 Bn in 2022
It is projected to grow at a CAGR of 5.8% from 2023 to 2031
Growth in prevalence of acute sinusitis and speedy approval of sinusitis therapeutics
The hospital pharmacies segment accounted for the largest share in 2022
North America was the dominant region in 2022
Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy’s Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Abbott Laboratories, Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co., Inc., AstraZeneca plc, Amneal Pharmaceuticals LLC, GlaxoSmithKline plc, Apotex, Inc., Hikma Pharmaceuticals plc, Wockhardt, and Mylan N.V.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sinusitis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Sinusitis Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Disease Type/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Sinusitis Treatment Market Analysis and Forecast, by Disease Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Type, 2017–2031
6.3.1. Acute Sinusitis
6.3.2. Sub-acute Sinusitis
6.3.3. Chronic Sinusitis
6.4. Market Attractiveness, by Disease Type
7. Global Sinusitis Treatment Market Analysis and Forecast, by Treatment
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment, 2017–2031
7.3.1. Analgesics
7.3.2. Antibiotics
7.3.2.1. Cephalosporin
7.3.2.2. Macrolide
7.3.2.3. Penicillin
7.3.3. Antihistamines
7.3.4. Surgery
7.3.4.1. Endoscopy
7.3.4.2. Balloon Sinuplasty
7.3.5. Corticosteroids
7.3.6. Sulfonamides
7.3.7. Quinolones
7.4. Market Attractiveness, by Treatment
8. Global Sinusitis Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Topical
8.3.2. Nasal
8.3.3. Oral
8.3.4. Injectable
8.4. Market Attractiveness, by Route of Administration
9. Global Sinusitis Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Online Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Hospital Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Sinusitis Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Sinusitis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease Type, 2017–2031
11.2.1. Acute Sinusitis
11.2.2. Sub-acute Sinusitis
11.2.3. Chronic Sinusitis
11.3. Market Attractiveness, by Disease Type
11.4. Market Value Forecast, by Treatment, 2017–2031
11.4.1. Analgesics
11.4.2. Antibiotics
11.4.2.1. Cephalosporin
11.4.2.2. Macrolide
11.4.2.3. Penicillin
11.4.3. Antihistamines
11.4.4. Surgery
11.4.4.1. Endoscopy
11.4.4.2. Balloon Sinuplasty
11.4.5. Corticosteroids
11.4.6. Sulfonamides
11.4.7. Quinolones
11.5. Market Attractiveness, by Treatment
11.6. Market Value Forecast, by Route of Administration, 2017–2031
11.6.1. Topical
11.6.2. Nasal
11.6.3. Oral
11.6.4. Injectable
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by Distribution Channel, 2017–2031
11.8.1. Online Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Hospital Pharmacies
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Disease Type
11.11.2. By Treatment
11.11.3. By Route of Administration
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Sinusitis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease Type, 2017–2031
12.2.1. Acute Sinusitis
12.2.2. Sub-acute Sinusitis
12.2.3. Chronic Sinusitis
12.3. Market Attractiveness, by Disease Type
12.4. Market Value Forecast, by Treatment, 2017–2031
12.4.1. Analgesics
12.4.2. Antibiotics
12.4.2.1. Cephalosporin
12.4.2.2. Macrolide
12.4.2.3. Penicillin
12.4.3. Antihistamines
12.4.4. Surgery
12.4.4.1. Endoscopy
12.4.4.2. Balloon Sinuplasty
12.4.5. Corticosteroids
12.4.6. Sulfonamides
12.4.7. Quinolones
12.5. Market Attractiveness, by Treatment
12.6. Market Value Forecast, by Route of Administration, 2017–2031
12.6.1. Topical
12.6.2. Nasal
12.6.3. Oral
12.6.4. Injectable
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by Distribution Channel, 2017–2031
12.8.1. Online Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Hospital Pharmacies
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Disease Type
12.11.2. By Treatment
12.11.3. By Route of Administration
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Sinusitis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease Type, 2017–2031
13.2.1. Acute Sinusitis
13.2.2. Sub-acute Sinusitis
13.2.3. Chronic Sinusitis
13.3. Market Attractiveness, by Disease Type
13.4. Market Value Forecast, by Treatment, 2017–2031
13.4.1. Analgesics
13.4.2. Antibiotics
13.4.2.1. Cephalosporin
13.4.2.2. Macrolide
13.4.2.3. Penicillin
13.4.3. Antihistamines
13.4.4. Surgery
13.4.4.1. Endoscopy
13.4.4.2. Balloon Sinuplasty
13.4.5. Corticosteroids
13.4.6. Sulfonamides
13.4.7. Quinolones
13.5. Market Attractiveness, by Treatment
13.6. Market Value Forecast, by Route of Administration, 2017–2031
13.6.1. Topical
13.6.2. Nasal
13.6.3. Oral
13.6.4. Injectable
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by Distribution Channel, 2017–2031
13.8.1. Online Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Hospital Pharmacies
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Disease Type
13.11.2. By Treatment
13.11.3. By Route of Administration
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Sinusitis Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease Type, 2017–2031
14.2.1. Acute Sinusitis
14.2.2. Sub-acute Sinusitis
14.2.3. Chronic Sinusitis
14.3. Market Attractiveness, by Disease Type
14.4. Market Value Forecast, by Treatment, 2017–2031
14.4.1. Analgesics
14.4.2. Antibiotics
14.4.2.1. Cephalosporin
14.4.2.2. Macrolide
14.4.2.3. Penicillin
14.4.3. Antihistamines
14.4.4. Surgery
14.4.4.1. Endoscopy
14.4.4.2. Balloon Sinuplasty
14.4.5. Corticosteroids
14.4.6. Sulfonamides
14.4.7. Quinolones
14.5. Market Attractiveness, by Treatment
14.6. Market Value Forecast, by Route of Administration, 2017–2031
14.6.1. Topical
14.6.2. Nasal
14.6.3. Oral
14.6.4. Injectable
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by Distribution Channel, 2017–2031
14.8.1. Online Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Hospital Pharmacies
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Disease Type
14.11.2. By Treatment
14.11.3. By Route of Administration
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Sinusitis Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Disease Type, 2017–2031
15.2.1. Acute Sinusitis
15.2.2. Sub-acute Sinusitis
15.2.3. Chronic Sinusitis
15.3. Market Attractiveness, by Disease Type
15.4. Market Value Forecast, by Treatment, 2017–2031
15.4.1. Analgesics
15.4.2. Antibiotics
15.4.2.1. Cephalosporin
15.4.2.2. Macrolide
15.4.2.3. Penicillin
15.4.3. Antihistamines
15.4.4. Surgery
15.4.4.1. Endoscopy
15.4.4.2. Balloon Sinuplasty
15.4.5. Corticosteroids
15.4.6. Sulfonamides
15.4.7. Quinolones
15.5. Market Attractiveness, by Treatment
15.6. Market Value Forecast, by Route of Administration, 2017–2031
15.6.1. Topical
15.6.2. Nasal
15.6.3. Oral
15.6.4. Injectable
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by Distribution Channel, 2017–2031
15.8.1. Online Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Hospital Pharmacies
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Disease Type
15.11.2. By Treatment
15.11.3. By Route of Administration
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Sun Pharmaceutical Industries, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Disease Type Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Pfizer, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Disease Type Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Disease Type Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Fresenius Kabi USA, LLC
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Disease Type Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Dr. Reddy’s Laboratories, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Disease Type Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Novartis AG
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Disease Type Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Teva Pharmaceutical Industries Ltd.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Disease Type Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Sanofi
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Disease Type Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Abbott Laboratories
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Disease Type Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Bayer AG
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Disease Type Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Eli Lilly and Company
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Disease Type Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Bristol-Myers Squibb
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Disease Type Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Merck & Co., Inc.
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Disease Type Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
16.3.14. AstraZeneca plc
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Disease Type Portfolio
16.3.14.3. Financial Overview
16.3.14.4. SWOT Analysis
16.3.14.5. Strategic Overview
16.3.15. Amneal Pharmaceuticals LLC
16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.15.2. Disease Type Portfolio
16.3.15.3. Financial Overview
16.3.15.4. SWOT Analysis
16.3.15.5. Strategic Overview
16.3.16. GlaxoSmithKline plc
16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.16.2. Disease Type Portfolio
16.3.16.3. Financial Overview
16.3.16.4. SWOT Analysis
16.3.16.5. Strategic Overview
16.3.17. Apotex, Inc.
16.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.17.2. Disease Type Portfolio
16.3.17.3. Financial Overview
16.3.17.4. SWOT Analysis
16.3.17.5. Strategic Overview
16.3.18. Hikma Pharmaceuticals plc
16.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.18.2. Disease Type Portfolio
16.3.18.3. Financial Overview
16.3.18.4. SWOT Analysis
16.3.18.5. Strategic Overview
16.3.19. Wockhardt
16.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.19.2. Disease Type Portfolio
16.3.19.3. Financial Overview
16.3.19.4. SWOT Analysis
16.3.19.5. Strategic Overview
16.3.20. Mylan N.V.
16.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.20.2. Disease Type Portfolio
16.3.20.3. Financial Overview
16.3.20.4. SWOT Analysis
16.3.20.5. Strategic Overview
List of Tables
Table 01: Global Sinusitis Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 02: Global Sinusitis Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 03: Global Sinusitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Sinusitis Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 05: Global Sinusitis Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Sinusitis Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Sinusitis Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 08: North America Sinusitis Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 9: North America Sinusitis Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 10: North America Sinusitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Sinusitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Sinusitis Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 13: Europe Sinusitis Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 14: Europe Sinusitis Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 15: Europe Sinusitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Sinusitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Sinusitis Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 18: Asia Pacific Sinusitis Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 19: Asia Pacific Sinusitis Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 20: Asia Pacific Sinusitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Latin America Sinusitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Sinusitis Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 23: Latin America Sinusitis Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 24: Latin America Sinusitis Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 25: Latin America Sinusitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Middle East & Africa Sinusitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Sinusitis Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031
Table 28: Middle East & Africa Sinusitis Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031
Table 29: Middle East & Africa Sinusitis Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 30: Middle East & Africa Sinusitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Sinusitis Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Sinusitis Treatment Market Revenue (US$ Mn), by Disease Type, 2022
Figure 03: Global Sinusitis Treatment Market Value Share, by Disease Type, 2022
Figure 04: Global Sinusitis Treatment Market Revenue (US$ Mn), by Treatment, 2022
Figure 05: Global Sinusitis Treatment Market Value Share, by Treatment, 2022
Figure 06: Global Sinusitis Treatment Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 07: Global Sinusitis Treatment Market Value Share, by Route of Administration, 2022
Figure 08: Global Sinusitis Treatment Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 09: Global Sinusitis Treatment Market Value Share, by Distribution Channel, 2022
Figure 10: Global Sinusitis Treatment Market Value Share, by Region, 2022
Figure 11: Global Sinusitis Treatment Market Value (US$ Mn) Forecast, 2022–2031
Figure 12: Global Sinusitis Treatment Market Value Share Analysis, by Disease Type, 2022–2031
Figure 13: Global Sinusitis Treatment Market Attractiveness Analysis, by Disease Type, 2023–2031
Figure 14: Global Sinusitis Treatment Market Value Share Analysis, by Treatment, 2022–2031
Figure 15: Global Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 16: Global Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 17: Global Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 18: Global Sinusitis Treatment Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 19: Global Sinusitis Treatment Market Value Share, by Distribution Channel, 2022
Figure 20: Global Sinusitis Treatment Market Value Share Analysis, by Region, 2022–2031
Figure 21: Global Sinusitis Treatment Market Attractiveness Analysis, by Region, 2022-2031
Figure 22: North America Sinusitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 23: North America Sinusitis Treatment Market Attractiveness Analysis, by Country, 2023–2031
Figure 24: North America Sinusitis Treatment Market Value Share Analysis, by Country, 2022–2031
Figure 25: North America Sinusitis Treatment Market Value Share Analysis, by Disease Type, 2022–2031
Figure 26: North America Sinusitis Treatment Market Value Share Analysis, by Treatment, 2022–2031
Figure 27: North America Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 28: North America Sinusitis Treatment Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 29: North America Sinusitis Treatment Market Attractiveness Analysis, by Disease Type, 2023–2031
Figure 30: North America Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 31: North America Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 32: North America Sinusitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 33: Europe Sinusitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 34: Europe Sinusitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 35: Europe Sinusitis Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 36: Europe Sinusitis Treatment Market Value Share Analysis, by Disease Type, 2022–2031
Figure 37: Europe Sinusitis Treatment Market Value Share Analysis, by Treatment, 2022–2031
Figure 38: Europe Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 39: Europe Sinusitis Treatment Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 40: Europe Sinusitis Treatment Market Attractiveness Analysis, by Disease Type, 2023–2031
Figure 41: Europe Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 42: Europe Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 43: Europe Sinusitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 44: Asia Pacific Sinusitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 45: Asia Pacific Sinusitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 46: Asia Pacific Sinusitis Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 47: Asia Pacific Sinusitis Treatment Market Value Share Analysis, by Disease Type, 2022–2031
Figure 48: Asia Pacific Sinusitis Treatment Market Value Share Analysis, by Treatment, 2022–2031
Figure 49: Asia Pacific Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 50: Asia Pacific Sinusitis Treatment Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 51: Asia Pacific Sinusitis Treatment Market Attractiveness Analysis, by Disease Type, 2023–2031
Figure 52: Asia Pacific Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 53: Asia Pacific Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 54: Asia Pacific Sinusitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 55: Latin America Sinusitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 56: Latin America Sinusitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 57: Latin America Sinusitis Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 58: Latin America Sinusitis Treatment Market Value Share Analysis, by Disease Type, 2022–2031
Figure 59: Latin America Sinusitis Treatment Market Value Share Analysis, by Treatment, 2022–2031
Figure 60: Latin America Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 61: Latin America Sinusitis Treatment Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 62: Latin America Sinusitis Treatment Market Attractiveness Analysis, by Disease Type, 2023–2031
Figure 63: Latin America Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 64: Latin America Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 65: Latin America Sinusitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 66: Middle East & Africa Sinusitis Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 67: Middle East & Africa Sinusitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 68: Middle East & Africa Sinusitis Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 69: Middle East & Africa Sinusitis Treatment Market Value Share Analysis, by Disease Type, 2022–2031
Figure 70: Middle East & Africa Sinusitis Treatment Market Value Share Analysis, by Treatment, 2022–2031
Figure 71: Middle East & Africa Sinusitis Treatment Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 72: Middle East & Africa Sinusitis Treatment Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 73: Middle East & Africa Sinusitis Treatment Market Attractiveness Analysis, by Disease Type, 2023–2031
Figure 74: Middle East & Africa Sinusitis Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 75: Middle East & Africa Sinusitis Treatment Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 76: Middle East & Africa Sinusitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Sinusitis Treatment Market
*86 figures and 60 tables includes